Access to DRDO drug 2-DG will improve in weeks: Dr. Reddy’s

DRDO invites more pharma firms to take up its production

Availability of 2-Deoxy-D-Glucose (2-DG), the drug developed by DRDO lab INMAS and approved for use as adjunct in treatment of moderate to severe COVID-19 patients, is set to improve in the weeks ahead with drugmaker Dr. Reddy’s Laboratories ramping up production. “I expect a very significant ramp up in the second half of June and subsequently in July,” said Deepak Sapra, CEO (API and Services) of Dr. Reddy’s. Stating that the company is licensee of DRDO, for the product launched last month following emergency use authorisation from the Drugs Controller General of India, he said in a matter of weeks the capacity will be enhanced to meet requirements of lakhs of patients.